Heron Therapeutics announces inclusion of SUSTOL® (Granisetron) ER Injection in NCCN®
Heron Therapeutics announced the inclusion of SUSTOL® (granisetron) extended-release injection as part of the National Comprehensive Cancer Network Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Antiemesis Version 1.2017. The NCCN has given SUSTOL a Category 1 recommendation. February 24, 2017